Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster

Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia. It is estimated that one in three adults will be affected by herpes zoster in their lifetime. Resea...

Full description

Saved in:
Bibliographic Details
Published inNursing for women's health Vol. 22; no. 5; pp. 417 - 422
Main Authors Sly, Jacqueline R., Harris, Allyssa L.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.10.2018
Subjects
chickenpox
herpes zoster
immunization
Nursing
recombinant zoster vaccine
shingles
Shingrix
vaccination
varicella zoster virus
Zostavax
Shingrix
herpes zoster
chickenpox
immunization
shingles
varicella zoster virus
Zostavax
recombinant zoster vaccine
vaccination
Online AccessGet full text

Cover

More Information
Summary:Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia. It is estimated that one in three adults will be affected by herpes zoster in their lifetime. Research evidence points to the need to prevent herpes zoster through vaccination. Since 2006, clinicians have been vaccinating adults with zoster vaccine live (brand name Zostavax), but the efficacy of this vaccine wanes with time and advanced age. In October 2017, the U.S. Food and Drug Administration approved recombinant zoster vaccine under the brand name Shingrix to prevent herpes zoster. Studies have shown significantly better efficacy of Shingrix versus Zostavax. This article summarizes new guidance regarding vaccination with Shingrix and discusses implications for women’s health.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1751-4851
1751-486X
DOI:10.1016/j.nwh.2018.07.004